COA Certified · Every Batch TestedTracked Shipping from Our U.S. FacilityLot-Matched COA · Batch TraceabilityFree Shipping on Orders Over $300≥99% Purity — HPLC + Mass SpecEndotoxin Tested · Sterility VerifiedCOA Certified · Every Batch TestedTracked Shipping from Our U.S. FacilityLot-Matched COA · Batch TraceabilityFree Shipping on Orders Over $300≥99% Purity — HPLC + Mass SpecEndotoxin Tested · Sterility Verified
For laboratory research use only. Not for human consumption.
All ProductsAP™ SeriesResearch PeptidesPeptide BlendsLiquid SpraysDissolving StripsTabletsBioregulatorsResearch BundlesLab Supplies Search

CJC-1295 (NO DAC) + Ipamorelin — Research Summary

Research Use Only · Not for Human or Veterinary Use

Synergistic GH secretagogue combination for pulsatile growth hormone release res

CJC-1295 (NO DAC) + Ipamorelin

An evidence summary of published preclinical research on CJC-1295 (NO DAC) + Ipamorelin. This page is educational and summarizes findings reported in third-party scientific literature. No claims are made regarding safety or efficacy in humans.

Molecular Data

FORMULA Blend — CJC: C152H252N44O42 / Ipamorelin: C38H49N9O5
MOLECULAR WEIGHT CJC: 3,367.9 g/mol / Ipamorelin: 711.85 g/mol
SEQUENCE CJC: 29-amino acid GHRH analog / Ipamorelin: pentapeptide

Compound Overview

This combination pairs CJC-1295 without DAC (a Growth Hormone Releasing Hormone analog) with Ipamorelin (a selective growth hormone secretagogue receptor agonist). Together, they are one of the most widely studied GH secretagogue combinations in peptide research, examined in preclinical models for pulsatile GH release patterns.

Reported Mechanism (Preclinical)

CJC-1295 acts on the GHRH receptor at the pituitary, amplifying the natural GH pulse signal. Ipamorelin acts on the ghrelin/GHS receptor as a selective agonist, triggering GH release without significantly affecting cortisol, prolactin, or ACTH. When combined, CJC-1295 amplifies the pulse amplitude while Ipamorelin increases pulse frequency, producing a synergistic elevation in total GH output.

Mechanisms described above are reported in preclinical (animal and in vitro) literature and have not been established for human use.

Key Research Highlights

  • Demonstrated synergistic GH elevation exceeding either compound alone in preclinical models
  • Ipamorelin showed highly selective GH release without cortisol or prolactin elevation
  • CJC-1295 extended the duration of GH pulse in pharmacokinetic studies
  • Combination maintained pulsatile GH release pattern, preserving physiological feedback
  • Research suggests favorable effects on body composition parameters in animal models

Published References

  1. Prolonged stimulation of growth hormone secretion by CJC-1295
    J Clin Endocrinol Metab, 2006
  2. Ipamorelin, a new growth-hormone-releasing peptide
    Eur J Endocrinol, 1998
  3. Growth hormone secretagogues: clinical applications
    Endocr Dev, 2010

Available for Research

Lab-tested, third-party COA published, ships from the U.S.

View Product · CJC-1295 (NO DAC) + Ipamorelin View COA Library
Compliance Notice: American Peptides products are sold strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature, summarizes findings from preclinical literature, and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution's safety protocols and applicable laws.